KATAKAMI Naoto ≪Metabolic Medicine≫ “The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects with Type 2 Diabetes: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial”
Publish Circulation 121:2584-2591(2010)
This is the first study to directly compare the effect of cilostazol, a phosphodiesterase III inhibitor with antiplatelet, antithrombotic, vasodilatory, and antiproliferative effects, and aspirin on the progression of atherosclerosis in diabetic patients. In this international, prospective, randomized, open, blinded-endpoint study involving a total of 329 Asian type 2 diabetic patients suspected of peripheral artery disease, we found that cilostazol treatment potently and safely inhibited the progression of carotid intima media thickness (IMT), an established surrogate marker of cardiovascular events, compared to aspirin treatment during a 2-year observation period. Our findings suggest that cilostazol is a more effective anti-atherosclerotic agent than aspirin in patients with type 2 diabetes.